共 43 条
[1]
Rosenstock J(2021)Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Lancet 398 143-155
[2]
Wysham C(2021)Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes N Engl J Med 385 503-515
[3]
Frias JP(2021)Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial Lancet 398 583-598
[4]
Frías JP(2021)Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Lancet 398 1811-1824
[5]
Davies MJ(2022)Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial JAMA 327 534-545
[6]
Rosenstock J(2021)9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022 Diabetes Care 45 S125-S143
[7]
Ludvik B(2019)Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States Diabetes Obes Metab 21 920-929
[8]
Giorgino F(2022)Greater adherence and persistence with injectable dulaglutide compared with injectable semaglutide at 1-Year follow-up: data from US clinical practice Clin Ther 44 537-554
[9]
Jódar E(2018)More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: a post hoc time-to-control analysis of LixiLan-O and LixiLan-L Diabetes Obes Metab 20 2314-2318
[10]
Del Prato S(2018)Identification of barriers to insulin therapy and approaches to overcoming them Diabetes Obes Metab 20 488-496